A new study in pet dogs treated with promising novel treatment regimens for the same cancer suggests that immune signatures found in blood samples could help identify poor responders early. The findings, published in Scientific Reports, point toward a future in which blood tests could help guide more personalized treatment decisions in both veterinary and human cancer care.